Inivata Wins One Nucleus BioNewsRound Award 2016 at Genesis Conference

2016, News

Inivata Wins One Nucleus BioNewsRound Award 2016 at Genesis Conference 

Inivata has been named as this year’s winner of the One Nucleus BioNewsRound Award, as announced at the Genesis 2016 in London.  The award reflects an online vote from peers following the selection of a six-strong shortlist by an expert panel.  Inivata was recognised for the announcement of its £31.5m Series A fundraising round to accelerate clinical studies of its ctDNA liquid biopsy technology.

Inivata uses a simple blood test, known as a liquid biopsy, to detect and analyse circulating tumour DNA (ctDNA) through an exclusive bioinformatics technology.  Inivata’s revolutionary approach, called InVision®, uses Next-Generation Sequencing along with an amplification process prior to sequencing and advanced, proprietary analytical methods enable the separation of true cancer mutations from background noise.  Inivata was founded in late 2014 from the Nitzan Rosenfeld Lab and draws on world-class, academic research from the University of Cambridge and Cancer Research UK.

Michael Stocum, Chief Executive Officer at Inivata, said:

“Inivata is honoured to receive the BioNewsAward 2016 and the recognition of our peers throughout the UK and further afield.  We look forward to further significant developments and announcements as we continue to advance the clinical validation of our technology and ultimately to play a part in revolutionising cancer testing and treatment and improving patient outcomes.”

Chief Executive of One Nucleus, Harriet Fear, said:

“The BioNewsRound award is much coveted and Inivata is an incredibly worthy winner.  The criteria is to showcase how the ‘news’ has impacted on the company, the sector, and of course ultimately has impacted or will impact on patients.  The award was incredibly close.   Importantly it is peer reviewed as the vote goes out to the sector.  We had over 1000 respond so the award is genuinely peer respected and appreciated – and a fantastic coup for Inivata – much deserved.”


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.


Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US) +44 (0)20 3709 5700, +1 516 503 0271


Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News

LinkedIn tracking code Twitter tracking code